Xenomics , Inc.

Industry:	Medical Testing & Clinical Laboratories
Revenues:	Under $20 Million
Employees:	10

Description

Xenomics, Inc. is the developer of next-generation molecular diagnostics products that address important health problems worldwide. Our mission is to apply our proprietary transrenal DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics that replace outdated blood, sputum, and tissue testing technologies many of which are not sufficiently sensitive and specific, and are often hazardous, and difficult to automate. The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets including infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, human forensics, and biodefense. Xenomics has made continuing progress in its clinical studies in infectious disease testing, particularly in the field of TB detection and therapeutic monitoring, HIV proviral DNA detection, and detection of early cancer genetic markers.

Products & Services

next-generation molecular diagnostics products

View More Statistics

Site Statistics

Monthly Unique Visitors:	802
Site Rank:	1,396,848
Trust Rating:	Neutral
Stats by

News Archive

Xenomics' Preliminary Investigation Leads the Company to Believe Sequenom Willfully Manipulated its Down Syndrome Data in its Presentations. Business Wire; 12/17/2009 NEW YORK -- Xenomics, Inc. (XNOM.PK), a developer...an ongoing internal investigation by Xenomics' personnel of the events surrounding...the Company - fraudulently inducing Xenomics into granting Sequenom an exclusive... ...more

Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology. Cancer Weekly; 11/24/2009 Xenomics, Inc. (XNOM.PK), a developer of...Papilloma Virus (HPV) DNA, based on Xenomics transrenal DNA technology. The technology...urine-based HPV screening (see also Xenomics, Inc.). "The HPV patent will be a... ...more

Xenomics Appoints Bruce A. Huebner as Chief Executive Officer and Board Member. Cancer Weekly; 10/20/2009 Xenomics, Inc. (Pink Sheets:XNOM.PK...Concurrent with Mr. Huebner's appointment, Xenomics announced the formation of TrovaGene...Robbins, VP Research and Development of Xenomics, which compared the Xenomics' test with... ...more